N-3 PUFA as an ergogenic supplement modulating muscle hypertrophy and strength: a systematic review

Crit Rev Food Sci Nutr. 2022;62(32):9000-9020. doi: 10.1080/10408398.2021.1939262. Epub 2021 Jun 15.

Abstract

There is growing evidence that suggests that n-3 polyunsaturated fatty acids (PUFA) may improve physical performance when combined with proper training through modulation of muscle hypertrophy, muscle strength, and delayed onset muscle soreness (DOMS). This systematic review aims to examine the effect and optimal dosage of n-3 PUFA supplementation on muscle hypertrophy, muscle strength, and DOMS when combined with physical exercise. The PubMed, Web of Science, MEDLINE Complete, CINAHL and SPORTDiscus databases were searched following the PRISMA guidelines. Randomized controlled trials performed with healthy humans were considered. Fifteen studies with a total of 461 individuals were included in this systematic review. All of them measured muscle function (short physical performance test, range of motion (ROM), electromechanical delay (EMD), muscle echo intensity or muscle quality) and DOMS. Fourteen studies evaluated muscle strength and only six assessed muscle hypertrophy. Our results demonstrated that n-3 PUFA does not improve muscle hypertrophy, muscle strength or skeletal muscle biomarkers of inflammation and muscle damage beyond the benefits obtained by the training itself. Nevertheless, n-3 PUFA improves DOMS recovery and muscle function (measured by ROM, EMD and muscle quality).

Keywords: Docosahexaenoic acid; eicosapentaenoic acid; muscle mass; muscle protein synthesis; omega 3; sports supplements.

Publication types

  • Systematic Review

MeSH terms

  • Dietary Supplements
  • Fatty Acids, Omega-3* / pharmacology
  • Humans
  • Hypertrophy
  • Muscle, Skeletal / physiology
  • Myalgia / drug therapy
  • Myalgia / prevention & control

Substances

  • Fatty Acids, Omega-3